Pathologic Response Rate After Concomitant Neo-Adjuvant Radiotherapy And Chemotherapy For Adenocarcinoma Of The Uterine Cervix
Olivier Poujade(Hôpital Beaujon), Fabien Reyal(Université Paris Sciences et Lettres), S. Alran(Institut Curie), Rémy Salmon(Clinique Saint Jean), Philippe Morice(Inserm), Fabrice Lécuru(Université Paris Cité), Roman Rouzier(Institut Curie), Jean-Michel Muray(Institut Gustave Roussy), Patrick Madélénat(Schiller International University), Patrice Mathevet(University of Lausanne)
Cited by 23
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
(untitled)
|Edinburgh Research Explorer|0|353
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282